FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076240635> ?p ?o ?g. }

• W2076240635 endingPage "1237" @default.
• W2076240635 startingPage "1237" @default.
• W2076240635 abstract "In patients with truly unresectable melanoma of the extremities, results after isolated limb perfusion (ILP) are absent in the literature. Complete response rates are probably lower than the reported 54% for locoregional recurrent melanoma. In these patients, ILP with melphalan and tumor necrosis factor alpha (TNF-alpha) could be superior to ILP with melphalan alone.Retrospective analysis with a median follow-up period of 21 months (interquartile range, 9-40 months).Two tertiary care cancer centers in the Netherlands.We assessed all 130 consecutive patients who underwent ILP for unresectable melanoma of the extremities, performed between 1978 and 2001. Of these patients, 38% had stage IIIA melanoma and 45% had stage IIIAB melanoma according to criteria of the MD Anderson Cancer Center. Lesions were considered unresectable on the basis of their size, number, or localization.Forty ILPs were performed with melphalan, and 90 were done with TNF-alpha and melphalan.Response rate, disease-free survival, limb salvage rate, and overall survival.In 45% of the patients, a complete response was attained after ILP with melphalan (95% confidence interval, 29%-61%) compared with 59% after ILP with TNF-alpha and melphalan (95% confidence interval, 49%-69%; P = .14). The time to complete response was 3 months (interquartile range, 2-6 months) vs 2 months (interquartile range, 1-3 months; P = .01), respectively. The recurrence rate and median limb recurrence-free survival were not significantly different for both ILP types. The overall limb salvage rate was 96%. Overall 5-year survival was 29% (95% confidence interval, 20%-38%). The ILP type was not an independent prognostic factor for complete response, nor was limb recurrence-free survival, whereas stage IIIA was a favorable prognostic factor (P = .01 and P = .02, respectively). Favorable prognostic factors for improved survival were complete response (P<.001) and a tumor size of 3 cm or less (P = .01).In more than half of the patients with truly unresectable melanoma of the extremities, a complete response was obtained after ILP with melphalan with or without TNF-alpha. The ILP type was not an independent prognostic factor for complete response, limb recurrence-free survival, or overall survival." @default.
• W2076240635 created "2016-06-24" @default.
• W2076240635 creator A5039296759 @default.
• W2076240635 date "2004-11-01" @default.
• W2076240635 modified "2023-09-27" @default.
• W2076240635 title "Isolated Limb Perfusion for Unresectable Melanoma of the Extremities" @default.
• W2076240635 cites W14310309 @default.
• W2076240635 cites W1831317193 @default.
• W2076240635 cites W1889451488 @default.
• W2076240635 cites W1962681190 @default.
• W2076240635 cites W1967535494 @default.
• W2076240635 cites W1975433208 @default.
• W2076240635 cites W1978730531 @default.
• W2076240635 cites W1979006071 @default.
• W2076240635 cites W1980628003 @default.
• W2076240635 cites W2007984865 @default.
• W2076240635 cites W2014895860 @default.
• W2076240635 cites W2019538674 @default.
• W2076240635 cites W2020666642 @default.
• W2076240635 cites W2028269517 @default.
• W2076240635 cites W2033005592 @default.
• W2076240635 cites W2037768641 @default.
• W2076240635 cites W2065370130 @default.
• W2076240635 cites W2065807715 @default.
• W2076240635 cites W2084994508 @default.
• W2076240635 cites W2095493818 @default.
• W2076240635 cites W2125837906 @default.
• W2076240635 cites W2131365547 @default.
• W2076240635 cites W2131887263 @default.
• W2076240635 cites W2170362455 @default.
• W2076240635 cites W2397516084 @default.
• W2076240635 cites W2408523293 @default.
• W2076240635 cites W2409873850 @default.
• W2076240635 cites W2412650394 @default.
• W2076240635 cites W327367050 @default.
• W2076240635 cites W2153653317 @default.
• W2076240635 doi "https://doi.org/10.1001/archsurg.139.11.1237" @default.
• W2076240635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15545572" @default.
• W2076240635 hasPublicationYear "2004" @default.
• W2076240635 type Work @default.
• W2076240635 sameAs 2076240635 @default.
• W2076240635 citedByCount "74" @default.
• W2076240635 countsByYear W20762406352012 @default.
• W2076240635 countsByYear W20762406352013 @default.
• W2076240635 countsByYear W20762406352014 @default.
• W2076240635 countsByYear W20762406352015 @default.
• W2076240635 countsByYear W20762406352016 @default.
• W2076240635 countsByYear W20762406352017 @default.
• W2076240635 countsByYear W20762406352018 @default.
• W2076240635 countsByYear W20762406352019 @default.
• W2076240635 countsByYear W20762406352020 @default.
• W2076240635 countsByYear W20762406352021 @default.
• W2076240635 countsByYear W20762406352022 @default.
• W2076240635 countsByYear W20762406352023 @default.
• W2076240635 crossrefType "journal-article" @default.
• W2076240635 hasAuthorship W2076240635A5039296759 @default.
• W2076240635 hasBestOaLocation W20762406351 @default.
• W2076240635 hasConcept C119060515 @default.
• W2076240635 hasConcept C126322002 @default.
• W2076240635 hasConcept C141071460 @default.
• W2076240635 hasConcept C167135981 @default.
• W2076240635 hasConcept C2776694085 @default.
• W2076240635 hasConcept C2777658100 @default.
• W2076240635 hasConcept C2778684742 @default.
• W2076240635 hasConcept C44249647 @default.
• W2076240635 hasConcept C502942594 @default.
• W2076240635 hasConcept C71924100 @default.
• W2076240635 hasConceptScore W2076240635C119060515 @default.
• W2076240635 hasConceptScore W2076240635C126322002 @default.
• W2076240635 hasConceptScore W2076240635C141071460 @default.
• W2076240635 hasConceptScore W2076240635C167135981 @default.
• W2076240635 hasConceptScore W2076240635C2776694085 @default.
• W2076240635 hasConceptScore W2076240635C2777658100 @default.
• W2076240635 hasConceptScore W2076240635C2778684742 @default.
• W2076240635 hasConceptScore W2076240635C44249647 @default.
• W2076240635 hasConceptScore W2076240635C502942594 @default.
• W2076240635 hasConceptScore W2076240635C71924100 @default.
• W2076240635 hasIssue "11" @default.
• W2076240635 hasLocation W20762406351 @default.
• W2076240635 hasLocation W20762406352 @default.
• W2076240635 hasOpenAccess W2076240635 @default.
• W2076240635 hasPrimaryLocation W20762406351 @default.
• W2076240635 hasRelatedWork W2003938723 @default.
• W2076240635 hasRelatedWork W2047967234 @default.
• W2076240635 hasRelatedWork W2061253854 @default.
• W2076240635 hasRelatedWork W2076240635 @default.
• W2076240635 hasRelatedWork W2118496982 @default.
• W2076240635 hasRelatedWork W2439875401 @default.
• W2076240635 hasRelatedWork W2981372661 @default.
• W2076240635 hasRelatedWork W3162511055 @default.
• W2076240635 hasRelatedWork W4238867864 @default.
• W2076240635 hasRelatedWork W2525756941 @default.
• W2076240635 hasVolume "139" @default.
• W2076240635 isParatext "false" @default.
• W2076240635 isRetracted "false" @default.
• W2076240635 magId "2076240635" @default.
• W2076240635 workType "article" @default.